OBJECTIVES: To determine whether disease activity verified by laboratorial parameters is associated with a higher frequency of hypertension in patients with systemic lupus erythematosus (SLE) without renal impairment and to investigate factors that could influence this hypertension. METHOD: This study included 102 controls, 70 patients with inactive SLE, and 53 patients with active SLE without renal impairment. We evaluated T helper type 1 (Th1)/Th2 lineage cytokines, nitric oxide (NO), insulin resistance (IR), and oxidative stress. RESULTS: Patients with active SLE had a higher probability of developing hypertension compared to controls [odds ratio (OR) 3.833, 95% confidence interval (CI) 1.806-8.137, p < 0.0003] and patients with inactive SLE (OR 2.215, 95% CI 1.032-4.752, p = 0.0394). Active SLE patients had a higher interleukin (IL)-12/IL-4 ratio (p < 0.05) than both controls and inactive SLE patients. Protein oxidation was significantly higher in patients with active SLE than in the control group and in patients with inactive SLE (p < 0.01 and p < 0.05, respectively). Multivariate analysis revealed an association between the presence of hypertension and he levels of glucose (p = 0.0276), insulin (p = 0.0498), hydroperoxides (p = 0.0221), IFN-γ (p = 0.0494), IL-17 (p = 0.0272), IL-12/IL-10 (p = 0.0373), IFN-γ/IL-10 (p = 0.0142), IFN-γ/IL-4 (p = 0.0320), and adiponectin (p = 0.0433). CONCLUSIONS: Patients with active SLE without renal impairment had an increased frequency of high blood pressure (43.4%) compared with patients with inactive SLE (25.7%) and controls (16.7%). Hypertension was associated with serologically active disease and was influenced by an increased Th1/Th2 ratio and oxidative stress.
OBJECTIVES: To determine whether disease activity verified by laboratorial parameters is associated with a higher frequency of hypertension in patients with systemic lupus erythematosus (SLE) without renal impairment and to investigate factors that could influence this hypertension. METHOD: This study included 102 controls, 70 patients with inactive SLE, and 53 patients with active SLE without renal impairment. We evaluated T helper type 1 (Th1)/Th2 lineage cytokines, nitric oxide (NO), insulin resistance (IR), and oxidative stress. RESULTS:Patients with active SLE had a higher probability of developing hypertension compared to controls [odds ratio (OR) 3.833, 95% confidence interval (CI) 1.806-8.137, p < 0.0003] and patients with inactive SLE (OR 2.215, 95% CI 1.032-4.752, p = 0.0394). Active SLEpatients had a higher interleukin (IL)-12/IL-4 ratio (p < 0.05) than both controls and inactive SLEpatients. Protein oxidation was significantly higher in patients with active SLE than in the control group and in patients with inactive SLE (p < 0.01 and p < 0.05, respectively). Multivariate analysis revealed an association between the presence of hypertension and he levels of glucose (p = 0.0276), insulin (p = 0.0498), hydroperoxides (p = 0.0221), IFN-γ (p = 0.0494), IL-17 (p = 0.0272), IL-12/IL-10 (p = 0.0373), IFN-γ/IL-10 (p = 0.0142), IFN-γ/IL-4 (p = 0.0320), and adiponectin (p = 0.0433). CONCLUSIONS:Patients with active SLE without renal impairment had an increased frequency of high blood pressure (43.4%) compared with patients with inactive SLE (25.7%) and controls (16.7%). Hypertension was associated with serologically active disease and was influenced by an increased Th1/Th2 ratio and oxidative stress.
Authors: Jingjing Liang; Thu H Le; Digna R Velez Edwards; Bamidele O Tayo; Kyle J Gaulton; Jennifer A Smith; Yingchang Lu; Richard A Jensen; Guanjie Chen; Lisa R Yanek; Karen Schwander; Salman M Tajuddin; Tamar Sofer; Wonji Kim; James Kayima; Colin A McKenzie; Ervin Fox; Michael A Nalls; J Hunter Young; Yan V Sun; Jacqueline M Lane; Sylvia Cechova; Jie Zhou; Hua Tang; Myriam Fornage; Solomon K Musani; Heming Wang; Juyoung Lee; Adebowale Adeyemo; Albert W Dreisbach; Terrence Forrester; Pei-Lun Chu; Anne Cappola; Michele K Evans; Alanna C Morrison; Lisa W Martin; Kerri L Wiggins; Qin Hui; Wei Zhao; Rebecca D Jackson; Erin B Ware; Jessica D Faul; Alex P Reiner; Michael Bray; Joshua C Denny; Thomas H Mosley; Walter Palmas; Xiuqing Guo; George J Papanicolaou; Alan D Penman; Joseph F Polak; Kenneth Rice; Ken D Taylor; Eric Boerwinkle; Erwin P Bottinger; Kiang Liu; Neil Risch; Steven C Hunt; Charles Kooperberg; Alan B Zonderman; Cathy C Laurie; Diane M Becker; Jianwen Cai; Ruth J F Loos; Bruce M Psaty; David R Weir; Sharon L R Kardia; Donna K Arnett; Sungho Won; Todd L Edwards; Susan Redline; Richard S Cooper; D C Rao; Jerome I Rotter; Charles Rotimi; Daniel Levy; Aravinda Chakravarti; Xiaofeng Zhu; Nora Franceschini Journal: PLoS Genet Date: 2017-05-12 Impact factor: 6.020